• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

2024 Capital Raise

Investors

Share Info

Financial Info

Documents & Presentations

Company Profile

Advisors

Corporate Governance

2026 Capital Raise

2024 Capital Raise

2023 Capital Raise

Regulatory News Archive

Proposed Placing and Subscription to raise a minimum of £8.5 million

5

Wrap Retail Offer for up to £1 million

5

Results of Placing

5

Results of WRAP Retail Offer

5

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy